Long-term use (3 years or more) of imatinib, as monotherapy or in combination with bosentan, was reported in two cases of pulmonary arterial hypertension.
Case Report (n=2)
Does long-term imatinib treatment improve outcomes in patients with pulmonary arterial hypertension?
This report describes the first two cases of long-term imatinib use (3 years or more) for the treatment of pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is a life threatening condition characterised by progressive obliteration of the small pulmonary arteries leading to increased pulmonary arterial resistance and right heart failure. Treatment for PAH has developed in the last few years since the description of new pathways related to the disease.1 Recently, short term (6 months) use of imatinib, a platelet derived growth factor (PDGF) receptor antagonist, in combination with maximal PAH treatment (prostacyclin derivative, endothelin receptor antagonist, and type 5 phosphodiesterase inhibitor) has been shown to improve the haemodynamics and functional capacity in a single case of severe PAH.2 We here report the first two cases of the long term (3 years or more) use of imatinib, as monotherapy or in combination with bosentan, a dual endothelin receptor antagonist. …
Rogério Souza (Fri,) conducted a case report in Pulmonary arterial hypertension (n=2). Imatinib was evaluated. Long-term use (3 years or more) of imatinib, as monotherapy or in combination with bosentan, was reported in two cases of pulmonary arterial hypertension.